Spectral Diagnostics Inc. of Toronto, Ontario, named GeorgeJackowski president, succeeding Bob Gilson, who resigned.Jackowski is a director of the company and had been itsexecutive vice president and director of research anddevelopment.
Arcturus Pharmaceutical Corp. of Woburn, Mass., namedRichard J. Sharpe senior vice president of research,development and clinical affairs, and Lewis M. Branscomb to itsboard of directors. Sharpe, a co-founder of the company and amember of its board of directors, had been the vice presidentof R&D. Prior to that, he was a research scientist at RepligenCorp. Branscomb is an Albert Pratt Public Service Professor atthe John F. Kennedy School of Government at HarvardUniversity.
Cellcor Inc. of Newton, Mass., named Frederick M. Miesowiczsenior vice president of scientific affairs. Miesowicz wasbusiness director for the SteriCell division of Terumo MedicalCorp.
Ligand Pharmaceuticals Inc. of San Diego appointed Lloyd E.Flanders vice president, research and development planning,administration and project management. Lambert was vicepresident, new drug development, cardiovascular products atthe Parke-Davis research division of Warner-Lambert.
AutoImmune Inc. of Boston appointed Malcolm Fletcher vicepresident, clinical and regulatory affairs. Fletcher was medicaldirector at Cato Research Ltd.
Zynaxis Inc. of Malvern, Pa., appointed Michael Christie vicepresident of process development for the therapeutic division.Christie joins Zynaxis from SmithKline Beecham Chemicals,where he was director of chemical development.
Somanetics Corp. of Troy, Mich., appointed James P. Bagianchairman of its scientific advisory board. Bagian has been aNASA astronaut since 1980, and has logged more than 337hours in space. He is a flight surgeon, board certified inaerospace medicine.
Agouron Pharmaceuticals Inc. of San Diego appointed Michael E.Herman to its board of directors. Herman spent 16 years withMarion Laboratories Inc., where was executive vice presidentand chief financial officer.
Tago Inc. and BioSource International Inc. of San Francisconamed John Bergmann vice president of scientific affairs.Bergmann was associate director/cell culture R&D for CentocorInc.
(c) 1997 American Health Consultants. All rights reserved.